These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 21816053

  • 1. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
    Spooner AM, Deegan C, D'Arcy DM, Gowing CM, Donnelly MB, Corrigan OI.
    BMC Clin Pharmacol; 2011 Aug 04; 11():11. PubMed ID: 21816053
    [Abstract] [Full Text] [Related]

  • 2. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
    D'Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI.
    BMC Pharmacol Toxicol; 2012 Nov 08; 13():14. PubMed ID: 23136834
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.
    Wallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ.
    Intensive Care Med; 2001 Apr 08; 27(4):665-72. PubMed ID: 11398692
    [Abstract] [Full Text] [Related]

  • 4. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, Roberts JA.
    J Antimicrob Chemother; 2016 Jun 08; 71(6):1643-50. PubMed ID: 26957490
    [Abstract] [Full Text] [Related]

  • 5. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J, Min KL, Kang S, Yang S, Park MS, Wi J, Chang MJ.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0063321. PubMed ID: 34937189
    [Abstract] [Full Text] [Related]

  • 6. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, Lassig-Smith M, Roberts NA, Dunlop R, Hayashi Y, Wallis SC, Lipman J.
    J Antimicrob Chemother; 2014 Sep 22; 69(9):2508-16. PubMed ID: 24879665
    [Abstract] [Full Text] [Related]

  • 7. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME, Lipman J, Tett SE.
    Br J Clin Pharmacol; 2004 Sep 22; 58(3):259-68. PubMed ID: 15327585
    [Abstract] [Full Text] [Related]

  • 8. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F.
    Crit Care; 2006 Feb 22; 10(1):R26. PubMed ID: 16507147
    [Abstract] [Full Text] [Related]

  • 9. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A, Wicha SG, Dorn C, Kratzer A, Schleibinger M, Kees F, Heininger A, Kees MG, Häberle H.
    Crit Care; 2018 Dec 17; 22(1):341. PubMed ID: 30558639
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D.
    J Antimicrob Chemother; 2016 Jun 17; 71(6):1651-9. PubMed ID: 26869692
    [Abstract] [Full Text] [Related]

  • 14. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2019 Dec 20; 64(1):. PubMed ID: 31658965
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
    Guenter SG, Iven H, Boos C, Bruch HP, Muhl E.
    Pharmacotherapy; 2002 Feb 20; 22(2):175-83. PubMed ID: 11837556
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
    Fish DN, Teitelbaum I, Abraham E.
    Antimicrob Agents Chemother; 2005 Jun 20; 49(6):2421-8. PubMed ID: 15917542
    [Abstract] [Full Text] [Related]

  • 20. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM, Jarrett P, Wallis SC, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    J Antimicrob Chemother; 2015 Feb 20; 70(2):528-33. PubMed ID: 25336163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.